Incyte Corp (Incyte) discovers, develops, and commercializes proprietary drugs for the treatment of cancer and hematologic conditions. The company reports its business as a single segment, which focuses on the discovery, development, and commercialization of proprietary therapeutics. Its commercial products include Jakafi, Iclusig, Pemazyre, Monjuvi, and Opzelura.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's pipeline portfolio comprises drug compounds for the treatment of cancer and hematologic conditions. It is advancing the development of tafasitamab, Fc-engineered antibody against CD 19 and the compound is in clinical development for the treatment of B cell malignancies. Its pipeline products include: ruxolitinib for chronic GVHD, covid-19 associated cytokine storm; parsaclisib for mantle cell lymphoma; tafasitamab for chronic lymphocytic leukemia; itacitinib for myelofibrosis and others. The company signed a collaboration and license agreement with MorphoSys AG and MorphoSys US Inc to develop and commercialise MOR208 (tafasitamab), which is an investigational Fc engineered monoclonal antibody targeting molecule CD19 outside the US. In FY2022, the company spent US$1,585.9 million on its R&D, which as a percentage of revenue, stood at 46.7%.